Veradermics Insiders Sold $103M as Stock Peaked
Veradermics insiders including the CEO, CTO, and a board director collectively sold $103.12 million in stock at $106 to $111 per share in the two weeks after the August 11 earnings report. The stock n
Veradermics Insiders Sold $103M as Stock Peaked
NEW YORK, September 3 —
Veradermics, Incorporated (MANE) carries a $163.50 analyst consensus target, yet in the two weeks after its August 11 earnings report, every disclosed category of insider sold: CEO, CTO, a board director, and the largest shareholder collectively unloaded $103.12 million in stock at $106 to $111 per share. The stock now trades at $98.46, below every price at which they exited.
- $103.12M in insider sales Aug 12-19; zero purchases in the 90-day window; stock now at $98.46, below all exit prices.
- $820M cash, zero debt, $78M annual cash burn; no product revenue.
- Consensus analyst target $163.50; short interest 14.7% of float; institutional ownership 97.9%.
The Exit Was Coordinated, Not Coincidental
Director John W. Childs sold 100,000 shares on August 12 for $10.71 million, one day after the earnings 8-K. CEO Reid Alexander Waldman and CTO Timothy August Durso both sold August 17, raising $7.28 million and $4.69 million respectively; both also exercised options at $12.19 per share that same day before selling into the open market at $106 to $111. Montanova Capital sold 750,000 shares August 19 for $80.44 million, then exercised options on 300,000 more the next day. Waldman's sales reportedly ran under a preset trading plan. Four parties, eight days, zero offsetting purchases in a 90-day window: the unanimity of direction is what the preset-plan defense cannot explain.
The Pipeline Bet the Insiders Declined to Hold
New Haven-based Veradermics has 37 employees and no marketed product. Its lead asset, VDPHL01, is an oral, non-hormonal chronic treatment for androgenetic alopecia targeting men and women alike, setting it apart from existing hormonal agents. The pipeline extends to VDMN for common warts, VDAA for alopecia areata, and VDMC for molluscum contagiosum. The company holds $820 million in cash with no debt and burns $78 million annually. The earnings record offers little comfort: a 473.1% miss against a -$18.24 estimate the prior quarter, followed by a 9.4% beat most recently. Investors modeling the cash runway can stress-test scenarios with Basis Report's DCF calculator. The bull case lives and dies on VDPHL01 data.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| MANE | $4.1B | n/a | +158.3% |
| ORKA | $6.1B | n/a | +515.3% |
| COAG | $2.1B | n/a | +29.5% |
| SYRE | $7.7B | n/a | +426.5% |
| KLRA | $2.1B | n/a | -36.9% |
| DNTH | $5.9B | n/a | +332.4% |
When the Bull Case Gets Its Answer
Analysts carry a $163.50 consensus target, a 66% premium that requires VDPHL01 to establish a credible commercial timeline. The August 7 S-1 and the August 14 424B3 supplement, filed three days after the August 11 earnings 8-K, point to a capital raise that may come at prices below where insiders sold. Short interest at 14.7% of float shows existing skepticism. The number that settles the argument: a Phase 2 or Phase 3 readout on VDPHL01 with statistically significant efficacy. Until that arrives, the most concrete signal is $103.12 million in insider sales, zero purchases, and a stock below every exit price. Run the free Veradermics, Incorporated deep-dive to follow the next catalyst.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Veradermics insiders sell stock?
In the two weeks following its August 11 earnings report, CEO Reid Waldman, CTO Timothy Durso, board director John Childs, and shareholder Montanova Capital collectively liquidated $103.12 million in stock at $106 to $111 per share. Four parties sold without any offsetting purchases in the 90-day window.
What is Veradermics' cash position?
Veradermics holds $820 million in cash with zero debt and burns $78 million annually. The company has 37 employees and no marketed product yet.
What is VDPHL01?
VDPHL01 is Veradermics' lead asset, an oral, non-hormonal chronic treatment for androgenetic alopecia targeting men and women alike. It distinguishes itself from existing hormonal agents on the market.
What is the analyst price target for MANE?
Analysts carry a $163.50 consensus price target. The key catalyst that could validate this target is a Phase 2 or Phase 3 readout on VDPHL01 showing statistically significant efficacy.
What is short interest in MANE stock?
Short interest represents 14.7 percent of the float, reflecting market skepticism about the company's prospects. Institutional ownership stands at 97.9 percent.
In the two weeks following Veradermics' August 11 earnings report and a fresh S-1 registration filing, the company's CEO, CTO, a director, and its largest disclosed shareholder collectively sold more than $103 million in stock at prices between $106 and $111 per share. The stock has since fallen to $98.46 — below every price at which insiders exited.